ALDH1A1 as a Cancer Stem Cell Marker: Value of Immunohistochemical Expression in Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia, and Prostatic Adenocarcinoma

Authors: H. M. Abdelmoneim, N. A. Babtain, A. S. Barhamain, A. Z. Kufiah, A. S. Malibari, S. F. Munassar, R. S. Rawa

Abstract:

Introduction: Prostate cancer is one of the most common causes of morbidity and mortality in men in developed countries. Cancer Stem Cells (CSCs) could be responsible for the progression and relapse of cancer. Therefore, CSCs markers could provide a prognostic strategy for human malignancies. Aldehyde dehydrogenase 1A1 (ALDH1A1) activity has been shown to be associated with tumorigenesis and proposed to represent a functional marker for tumor initiating cells in various tumor types including prostate cancer. Material & Methods: We analyzed the immunohistochemical expression of ALDH1A1 in benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma and assessed their significant correlations in 50 TURP sections. They were microscopically interpreted and the results were correlated with histopathological types and tumor grade. Results: In different prostatic histopathological lesions we found that ALDH1A1 expression was low in BPH (13.3%) and PIN (6.7%) and then its expression increased with prostatic adenocarcinoma (40%), and this was statistically highly significant (P value = 0.02). However, in different grades of prostatic adenocarcinoma we found that the higher the Gleason grade the higher the expression for ALDH1A1 and this was statistically significant (P value = 0.02). We compared the expression of ALDH1A1 in PIN and prostatic adenocarcinoma. ALDH1A1 expression was decreased in PIN and highly expressed in prostatic adenocarcinoma and this was statistically significant (P value = 0.04). Conclusion: Increasing ALDH1A1 expression is correlated with aggressive behavior of the tumor. Immunohistochemical expression of ALDH1A1 might provide a potential approach to study tumorigenesis and progression of primary prostate carcinoma.

Keywords: ALDH1A1, BPH, PIN, prostatic adenocarcinoma.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1111574

References:

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics. CA: a cancer journal for clinicians. 2015;65(1):5-29.
[2] Valdes-Mora F, Clark SJ. Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene. 2015;34(13):1609-18.
[3] Felgueiras J, Silva JV, Fardilha M. Prostate cancer: the need for biomarkers and new therapeutic targets. Journal of Zhejiang University Science B. 2014;15(1):16-42.
[4] Dimov I, Visnjic M, Stefanovic V. Urothelial cancer stem cells. The Scientific World Journal. 2010;10:1400-15.
[5] Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755– 68.
[6] Bo Zou Shoujuan Sun Xiaojuan Qi Ping Ji. Aldehyde dehydrogenase activity is a cancer stem cell marker of tongue squamous cell carcinoma. Mol Med Rep. 2012 Apr; 5(4):1116–20.
[7] Van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer research. 2010;70(12):5163-73.
[8] Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Laboratory investigation. Journal of technical methods and pathology. 2010;90(2):234-44.
[9] Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–67.
[10] Egevad L, Norlen BJ, Norberg M. The value of multiple core biopsies for predicting the Gleason score of prostate cancer. BJU international. 2001;88(7):716-21.
[11] Yu L, Liu S, Zhang C, Zhang B, Simoes BM, Eyre R, et al. Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity. Oncotarget. 2013;4(12):2326-38.
[12] Xu SL, Liu S, Cui W, Shi Y, Liu Q, Duan JJ, et al. Aldehyde dehydrogenase 1A1 circumscribes high invasive glioma cells and predicts poor prognosis. American journal of cancer research. 2015;5(4):1471-83.
[13] Liu G-L, Yang H-J, Liu T, Lin Y-Z.Expression and significance of E-cadherin, N-cadherin, transforming growth factor-β1 and Twist in prostate cancer. Asian Pacific Journal of Tropical Medicine. 2014;7(1):76-82.
[14] Adamowicz J, Pokrywczynska M, Tworkiewicz J, Wolski Z, Drewa T. The relationship of cancer stem cells in urological cancers. Cent Eur J Urol. 2013;66:273-80.
[15] Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, et al. Characterization and clinical relevance of ALDH bright populations in prostate cancer. Clinical cancer research. 2013;19(19):5361-71.
[16] Matsika A, Srinivasan B, Day C, Mader SA, Kiernan DM, Broomfield A, et al. Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2. Pathology. 2015;47(7):622-8.
[17] Moreb JS, Mohuczy D, Ostmark B, Zucali JR. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer chemotherapy and pharmacology. 2007;59(1):127-36.
[18] Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Current stem cell research & therapy. 2008;3(4):237-46.
[19] A. Josephine, Clinicopathological Study of Prostatic Biopsies, 2014 Sep; 8(9): FC04–FC06.
[20] Michael K Brawer. Prostatic Intraepithelial Neoplasia: An Overview. Rev Urol. 2005; 7(Suppl 3): S11–S18.
[21] Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993 Aug; 150(2 Pt 1):379-85.
[22] Hassan A U, Hassan G, Zubeida Z R. Aims and objectives of histological studies of prostate. Universal Journalof Clinical Medicine. 2013;1(2):13-21.
[23] Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and pathogenesis of benign prostatic hyperplasia. BJU Int. 2008 Aug 5; 102(5):536-44.
[24] Bruskewitz RC. Quality of Life and Sexual Function in Patients with Benign Prostatic Hyperplasia. Rev Urol. 203; 5: 72–80.
[25] Notara M, Ahmed A. Benign prostate hyperplasia and stem cells: a new therapeutic opportunity. Cell biology and toxicology. 2012;28(6):435-42.
[26] Ferronika P, Triningsih FXE, Ghozali A, Moeljono A, Rahmayanti S, Shadrina AN, et al. p63 Cytoplasmic Aberrance is Associated with High Prostate Cancer Stem Cell Expression. Asian Pacific Journal of Cancer Prevention. 2012;13(5):1943-8.
[27] Prajapati A, Gupta S, Mistry B, Gupta S. Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts. BioMed research international. 2013;2013:107954.
[28] Fawzy MS, Mohamed RH, Elfayoumi AR. Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer. Medical oncology. 2015;32(3):74.
[29] De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. European urology. 2011;60(1):106-17.
[30] Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, et al. Prostate growth and inflammation. The Journal of steroid biochemistry and molecular biology. 2008;108(3-5):254-60.
[31] Epstein JI. Pathology of prostatic neoplasia. 3rd Edition . Philadelphia: Saunders Elsevier, 2011: 2726-2734.
[32] DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. The Lancet. 2003;361(9361):955-64.
[33] Hoogland AM, Kweldam CF, van Leenders GJ. Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review. BioMed research international. 2014;2014:341324.
[34] Vukovic B, Park PC, Al-Maghrabi J, Beheshti B, Sweet J, Evans A, Trachtenberg J, Squire J. Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene. 2003 Apr 3; 22(13):1978-87.
[35] Bostwick DG, Qian J. Atypical adenomatous hyperplasia of the prostate. Relationship with carcinoma in 217 whole-mount radical prostatectomies. Am J SurgPathol. 1995 May; 19(5):506-18.
[36] Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C, Green JE. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res. 2002 Sep 15; 62(18):5325-35.
[37] Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer. 1987 Feb 15; 59(4):788-94.
[38] McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol. 1986 Jan; 17(1):64-71.
[39] Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, et al. Characterization and clinical relevance of ALDH bright populations in prostate cancer. Clinical cancer research. 2013;19(19):5361-71.
[40] Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem cell reviews. 2011;7(2):292-306.